We examined the association between ABI3 expression and immunotherapeutic responsiveness, specifically in relation to immune checkpoint inhibitors like anti-PD-L1 and anti-PD-1 antibodies, by analyzing two pertinent cohorts, unveiling ABI3’s potential as a predictive marker for immune checkpoint blockade therapy sensitivity in cancer immunotherapy. Here, ABI3 is linked to cancer.